Literature DB >> 16207568

Autoimmune hepatitis.

Dwain L Thiele1.   

Abstract

Autoimmune hepatitis (AIH) is an intermittently progressive liver disease characterized by hypergammaglobulinemia, autoantibodies, predominately periportal hepatitis, and a favorable response to corticosteroid therapy in most cases. There are no pathognomonic markers of autoimmune liver disease; rather, the diagnosis must be based on the presence of a constellation of characteristic clinical, laboratory, and histologic features in patients without other causes of such liver pathology. Although prednisone or prednisolone are the mainstays in initial therapy of AIH, azathioprine or other drugs with similar immunosuppressive mechanisms are of benefit for steroid-sparing effects or for use as monotherapy to maintain long-term remission. A fraction of patients meeting diagnostic criteria for AIH remains in long-term remission following withdrawal of immunosuppressive therapies, but in most patients, this disease represents a chronic condition requiring life-long monitoring and therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207568     DOI: 10.1016/j.cld.2005.07.004

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

1.  Current Advances in the Treatment of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

2.  Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid.

Authors:  Karen Wallace; Paul A Flecknell; Alastair D Burt; Matthew C Wright
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  Pregnancy with autoimmune hepatitis.

Authors:  António Costa Braga; Carlos Vasconcelos; Jorge Braga
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

Review 4.  Inflammatory bowel disease in liver transplanted patients.

Authors:  Tajana Filipec Kanizaj; Maja Mijic
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.